Perspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt Purchases 12,829 Shares

Perspective Therapeutics, Inc. (NYSE:CATX) CFO Jonathan Robert Hunt acquired 12,829 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was bought at an average price of $3.82 per share, with a total value of $49,006.78. Following the acquisition, the chief financial officer now directly owns 48,800 shares of the company’s stock, valued at $186,416. The trade was a 35.66 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Perspective Therapeutics Trading Up 18.4 %

Shares of NYSE:CATX opened at $4.37 on Wednesday. Perspective Therapeutics, Inc. has a 12 month low of $2.28 and a 12 month high of $19.05. The stock’s fifty day moving average is $11.15.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting analysts’ consensus estimates of ($0.21). The company had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. Research analysts predict that Perspective Therapeutics, Inc. will post -0.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

CATX has been the subject of several analyst reports. Truist Financial started coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price for the company. Royal Bank of Canada lowered their target price on shares of Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a research note on Monday. UBS Group started coverage on shares of Perspective Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target on the stock. Oppenheimer lowered their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Finally, Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $24.00 to $5.00 in a report on Monday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.14.

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company increased its position in shares of Perspective Therapeutics by 8.9% in the third quarter. The Manufacturers Life Insurance Company now owns 20,514 shares of the company’s stock valued at $274,000 after acquiring an additional 1,672 shares during the last quarter. Sykon Capital LLC increased its position in shares of Perspective Therapeutics by 4.7% during the 2nd quarter. Sykon Capital LLC now owns 37,932 shares of the company’s stock worth $378,000 after purchasing an additional 1,717 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Perspective Therapeutics by 5.8% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 58,678 shares of the company’s stock worth $783,000 after purchasing an additional 3,211 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company’s stock valued at $88,000 after buying an additional 3,866 shares during the last quarter. Finally, nVerses Capital LLC bought a new position in shares of Perspective Therapeutics in the third quarter valued at $57,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.